{"filing":{"accession_number":"0001193125-26-339223","cik":"0001124105","ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"gyre-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/gyre-20260807.htm"},"events":[{"id":26123,"run_id":23725,"accession_number":"0001193125-26-339223","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Gyre Therapeutics' financial results for Q2 2026 and year-to-date results, including revenues of $29.1 million for Q2 and $53.5 million for six months, GAAP basic EPS of $(0.12), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27148,"accession_number":"0001193125-26-339223","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Gyre Therapeutics' financial results for Q2 2026 and year-to-date results, including revenues of $29.1 million for Q2 and $53.5 million for six months, GAAP basic EPS of $(0.12), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:08:18.953129+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27148,"accession_number":"0001193125-26-339223","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Gyre Therapeutics' financial results for Q2 2026 and year-to-date results, including revenues of $29.1 million for Q2 and $53.5 million for six months, GAAP basic EPS of $(0.12), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:08:18.953129+00:00","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-08-07"}]}